Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133)

Makoto Nishio, Shunichi Sugawara, Shinji Atagi, Hiroaki Akamatsu, Hiroshi Sakai, Isamu Okamoto, Koichi Takayama, Hidetoshi Hayashi, Yuki Nakagawa, Tomohisa Kawakami

Research output: Contribution to journalArticle

Abstract

Atezolizumab is effective and well-tolerated in patients with extensive-stage small-cell lung cancer (ES-SCLC). We examined atezolizumab's efficacy and safety in 42 Japanese patients with ES-SCLC via a subanalysis of the phase I/III IMpower133 trial. Addition of atezolizumab to chemotherapy improved overall survival and was generally well-tolerated, thus offering a potentially new treatment for Japanese patients with ES-SCLC.

Original languageEnglish
Pages (from-to)469-476.e1
JournalClinical Lung Cancer
Volume20
Issue number6
DOIs
Publication statusPublished - Nov 2019

Fingerprint

Small Cell Lung Carcinoma
Safety
Drug Therapy
Survival
MPDL3280A
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133). / Nishio, Makoto; Sugawara, Shunichi; Atagi, Shinji; Akamatsu, Hiroaki; Sakai, Hiroshi; Okamoto, Isamu; Takayama, Koichi; Hayashi, Hidetoshi; Nakagawa, Yuki; Kawakami, Tomohisa.

In: Clinical Lung Cancer, Vol. 20, No. 6, 11.2019, p. 469-476.e1.

Research output: Contribution to journalArticle

Nishio, M, Sugawara, S, Atagi, S, Akamatsu, H, Sakai, H, Okamoto, I, Takayama, K, Hayashi, H, Nakagawa, Y & Kawakami, T 2019, 'Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133)', Clinical Lung Cancer, vol. 20, no. 6, pp. 469-476.e1. https://doi.org/10.1016/j.cllc.2019.07.005
Nishio, Makoto ; Sugawara, Shunichi ; Atagi, Shinji ; Akamatsu, Hiroaki ; Sakai, Hiroshi ; Okamoto, Isamu ; Takayama, Koichi ; Hayashi, Hidetoshi ; Nakagawa, Yuki ; Kawakami, Tomohisa. / Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133). In: Clinical Lung Cancer. 2019 ; Vol. 20, No. 6. pp. 469-476.e1.
@article{ce4246d1d0844045b6f69f9705134614,
title = "Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133)",
abstract = "Atezolizumab is effective and well-tolerated in patients with extensive-stage small-cell lung cancer (ES-SCLC). We examined atezolizumab's efficacy and safety in 42 Japanese patients with ES-SCLC via a subanalysis of the phase I/III IMpower133 trial. Addition of atezolizumab to chemotherapy improved overall survival and was generally well-tolerated, thus offering a potentially new treatment for Japanese patients with ES-SCLC.",
author = "Makoto Nishio and Shunichi Sugawara and Shinji Atagi and Hiroaki Akamatsu and Hiroshi Sakai and Isamu Okamoto and Koichi Takayama and Hidetoshi Hayashi and Yuki Nakagawa and Tomohisa Kawakami",
year = "2019",
month = "11",
doi = "10.1016/j.cllc.2019.07.005",
language = "English",
volume = "20",
pages = "469--476.e1",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133)

AU - Nishio, Makoto

AU - Sugawara, Shunichi

AU - Atagi, Shinji

AU - Akamatsu, Hiroaki

AU - Sakai, Hiroshi

AU - Okamoto, Isamu

AU - Takayama, Koichi

AU - Hayashi, Hidetoshi

AU - Nakagawa, Yuki

AU - Kawakami, Tomohisa

PY - 2019/11

Y1 - 2019/11

N2 - Atezolizumab is effective and well-tolerated in patients with extensive-stage small-cell lung cancer (ES-SCLC). We examined atezolizumab's efficacy and safety in 42 Japanese patients with ES-SCLC via a subanalysis of the phase I/III IMpower133 trial. Addition of atezolizumab to chemotherapy improved overall survival and was generally well-tolerated, thus offering a potentially new treatment for Japanese patients with ES-SCLC.

AB - Atezolizumab is effective and well-tolerated in patients with extensive-stage small-cell lung cancer (ES-SCLC). We examined atezolizumab's efficacy and safety in 42 Japanese patients with ES-SCLC via a subanalysis of the phase I/III IMpower133 trial. Addition of atezolizumab to chemotherapy improved overall survival and was generally well-tolerated, thus offering a potentially new treatment for Japanese patients with ES-SCLC.

UR - http://www.scopus.com/inward/record.url?scp=85071137609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071137609&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2019.07.005

DO - 10.1016/j.cllc.2019.07.005

M3 - Article

C2 - 31466854

AN - SCOPUS:85071137609

VL - 20

SP - 469-476.e1

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 6

ER -